BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
월요일, 9월 28

Teladoc Health Inc

TDOCNYSE
Trade with Public
Trade with Public
$5.89
-0.20-3.28%
가까이에: Sep 28, 5:00 PM EST
$5.87
-0.0186-0.32%
시간외: 4:30 PM EST
개요뉴스실적 전망이벤트목표가재무심리지분 현황비교옵션주식 보고서

Teladoc Health Analyst Price Targets

Wall Street analyst price targets and consensus rating for Teladoc Health (TDOC).

Price Target Range — 12 Quarters

Analyst Consensus — 20 Analysts

8Buy
12Hold
Consensus RatingHold# Analysts20Avg. Consensus PT$9Upside to Avg. PT+51.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →
DateFirmAnalystActionRating ChangePrice Target
Aug 3, 2026CitigroupDaniel GrosslightPT CutNeutral$11→$8
Jul 30, 2026Canaccord GenuityRichard ClosePT CutBuy$11→$10
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Citigroup Maintains Neutral on Teladoc Health, Lowers Price Target to $7.5

Citigroup analyst Daniel Grosslight maintains Teladoc Health (NYSE:TDOC) with a Neutral and lowers the price target from $11 to $7.5.
Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on Teladoc Health, Lowers Price Target to $10

Canaccord Genuity analyst Richard Close maintains Teladoc Health (NYSE:TDOC) with a Buy and lowers the price target from $11 to $10.
Benzinga Newsdesk

PRO
Evercore ISI Group Maintains In-Line on Teladoc Health, Lowers Price Target to $7.5

Evercore ISI Group analyst Elizabeth Anderson maintains Teladoc Health (NYSE:TDOC) with a In-Line and lowers the price target from $10 to $7.5.
Benzinga Newsdesk

Synchrony Financial To Rally Around 25%? Here Are 10 Top Analyst Forecasts For Wednesday

Top analysts change outlook on top names. Baird, Canaccord Genuity, Needham, Stifel, Truist Securities raise price targets. See analyst ratings.
Avi Kapoor

PRO
Canaccord Genuity Maintains Buy on Teladoc Health, Raises Price Target to $11

Canaccord Genuity analyst Richard Close maintains Teladoc Health (NYSE:TDOC) with a Buy and raises the price target from $10 to $11.
Benzinga Newsdesk

PRO
Citigroup Maintains Neutral on Teladoc Health, Raises Price Target to $7

Citigroup analyst Daniel Grosslight maintains Teladoc Health (NYSE:TDOC) with a Neutral and raises the price target from $6 to $7.
Benzinga Newsdesk

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

시장 데이터 제공 Benzinga API

BenzingaBenzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved